Brief: Oncolytics Biotech Provides Positive Safety Update On The Third-Line Metastatic Colorectal Cancer Cohort Of Its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
31/03/2022 13:19
March 31 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® PROVIDES POSITIVE SAFETY UPDATE ON THE
THIRD-LINE METASTATIC COLORECTAL CANCER COHORT OF ITS
MULTI-INDICATION PHASE 1/2 GASTROINTESTINAL CANCER TRIAL
* ONCOLYTICS BIOTECH INC - INDEPENDENT REVIEW IDENTIFIED, NO
SAFETY CONCERNS IN TRIAL'S FINAL SAFETY RUN-IN
Source text for Eikon: ID:nPn4hLcHYa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer